The Zacks Analyst Blog Highlights: Johnson & Johnson, Tekmira Pharmaceuticals, GileadSciences, Allergan and Supernus Pharmaceuticals

News provided by

Aug 21, 2014, 09:30 ET

CHICAGO, Aug. 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Johnson & Johnson (NYSE:JNJ-Free Report), Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report), Gilead Sciences Inc. (Nasdaq:GILD-Free Report), Allergan Inc. (NYSE:AGN-Free Report) and Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday's Analyst Blog:

Healthcare Enjoys Growth Trends: 3 Stocks to Buy

The 2014 Q2 earnings season has been impressive for the Medical sector with 16.1% year-over-year earnings growth on 12.5% increase in revenues. Also, among the 94% sector participants reported so far, 78.7% delivered positive earnings surprises. Favorable industry trends in pharma and biotech primarily contributed to this robust growth.

Impressive Growth Trends in Pharma and Biotech

Pharmaceutical companies have been affected by genericization over the past few years. However, the worst of patent cliff is over and several companies are now on the recovery path.

Johnson & Johnson (NYSE:JNJ-Free Report) was the first major company from the drug manufacturing industry to post impressive second-quarter earnings. The NYSE ARCA Pharmaceutical Index is up almost 20.1% in the last year. So far in 2014, the index increased10%. As of Aug 11, 2014, the Standard & Poor's biotechnology index soared 13.6% since January, compared to the S&P 500's gain of 5.1%.

Pharma and bio-tech space witnessed a slew of IPOs in the last few quarters. Fifty three pharmaceutical and biotech firms launched IPOs this year. The segment also witnessed a flurry of new deals in therecent months. All these boosted investors' sentiment and thus pushed the stock prices up.

New Drugs & Increased Spending Boost Growth

Development of new drugs and an increase in healthcare spending also fueled growth of pharma and bio-tech stocks.

Throughout the first half of 2014, several important products gained approval by the Food and Drug Administration (FDA). A number of new drugs are also in the pipeline. Many companies have already announced FDA acceptance for filing of New Drug Application (NDA).

Amid all these, the Ebola outbreak is also making headlines. This has brought biotech companies such as Tekmira Pharmaceuticals Corp (Nasdaq:TKMR-Free Report) into the spotlight for their experimental Ebola disease treatments.

Meanwhile, Americans are currently in a better position to meet medical costs thanks to the rebound in the U.S. economy. This recovery has propelled healthcare spending. According to PricewaterhouseCoopers's (PwC) Health Research Institute, healthcare spending is expected to rise 6.8% in 2015, up from 6.5% increase forecasted for this year.

The Affordable Care Act (ACA), or "Obamacare," also pushed healthcare spending upward. An aging population also significantly contributed to healthcare spending. Most of the baby boomers are expected to turn 65 and older between 2012 and 2030. Further, U.S. Census Bureau stated the nation's 65-and-older population is anticipated to reach 83.7 million in 2050.

Banking on these encouraging factors along with ever increasing demand in emerging markets, drug manufacturing and biotech companies are poised to grow in the coming quarters.

3 Medical Stocks to Buy Now

Gilead Sciences Inc. (Nasdaq:GILD-Free Report)is a biopharmaceutical company that develops and commercializes medicines for treatment of life threatening diseases. Gilead Sciences posted second-quarter earnings per share of $2.32, surpassing the Zacks Consensus Estimate of $1.61. Moreover, the Zacks Consensus Estimate for the company's current year earnings increased 18.4% to $7.26 per share in the 30 days ago.

Last Friday, Gilead won a dispute with Roche related to rights of its hepatitis C drug, Sovaldi. Shares of the Gilead rose sharply and touched a new high of $99.49. It's good news for Gilead since IMS Health revealed that prescriptions for Sovaldi amount to more than all other Hepatitis C treatments combined.

This Zacks Rank #1 (Strong Buy) stock has an attractive PEG ratio of 0.46. In the last three months, the stock gained 23.4%.

Allergan Inc. (NYSE:AGN-Free Report) operates as a multi-specialty health care company. Allergan reported second quarter 2014 earnings of $1.51 per share, above the Zacks Consensus Estimate of $1.44. Earnings also climbed 23.8% from the year-ago quarter.

The company expects third quarter earnings in the range of $1.44–$1.47 per share. The Zacks Consensus Estimate currently stands at $1.44. The company also expects 2014 earnings to increase $5.74–$5.80 per share, well above the Zacks Consensus Estimate of $5.70 per share.

Expected earnings growth rate for this Zacks Rank #1 (Strong Buy) stock is 21.4% for this year, much above the industry growth rate of 0.5%.

Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN-Free Report) is a specialty pharmaceutical company which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the U.S.

Supernus posted second-quarter 2014 earnings per share of 6 cents, which compared favorably with the Zacks Consensus Estimate of a loss of 18 cents and the year-ago loss of 57 cents. Revenues were $29.7 million, up 10.5% from the year-ago quarter. Revenues were well above the Zacks Consensus Estimate of $19 million.

Supernus has raised its annual revenue guidance to $105 million (previous guidance: $75 million − $85 million).

Expected earnings growth rate for this Zacks Rank #2 (Buy) stock is 100.7% for 2014, significantly higher than the industry growth rate of 24.3%.

Bottom Line

These stocks with strong fundamentals and growth prospects are poised to gain in the near future. While it is expected that most of the stocks in the pharma and bio-tech space will gain, those with a favorable Zacks Rank may ensure outperformance.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on JNJ - FREE

Get the full Report on TKMR - FREE

Get the full Report on GILD - FREE

Get the full Report on AGN - FREE

Get the full Report on SUPN - FREE

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.